Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Viking Therapeutics, Inc. (VKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 85.44% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-07-29
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 85.43%, a 3.70% increase year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 82.38%, a 0.63% decline year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 82.90%, a 2.74% increase year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 80.69%, a 7.58% decline year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 83.20%, a 0.36% increase from fiscal 2024.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 82.90%, a 1.97% increase from fiscal 2023.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 81.30%, a 6.12% decline from fiscal 2022.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 86.60%, a 2.24% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 85.44% 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 85.43% 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | 83.20% 10-K · filed 2026-02-11 | |||
| 2025-09-30 | 82.83% 10-Q · filed 2025-10-23 | |||
| 2025-06-30 | 82.50% 10-Q · filed 2025-07-23 | |||
| 2025-03-31 | 82.38% 10-Q · filed 2025-04-24 | |||
| 2024-12-31 | 82.90% 10-K · filed 2026-02-11 | |||
| 2024-09-30 | 82.86% 10-Q · filed 2024-10-23 | |||
| 2024-06-30 | 83.00% 10-Q · filed 2024-07-24 | |||
| 2024-03-31 | 82.90% 10-Q · filed 2024-04-25 | |||
| 2023-12-31 | 81.30% 10-K · filed 2026-02-11 | |||
| 2023-09-30 | 81.29% 10-Q · filed 2023-10-25 | |||
| 2023-06-30 | 80.88% 10-Q · filed 2023-07-26 | |||
| 2023-03-31 | 80.69% 10-Q · filed 2023-04-26 | |||
| 2022-12-31 | 86.60% 10-K · filed 2025-02-26 | |||
| 2022-09-30 | 87.00% 10-Q · filed 2022-10-26 | |||
| 2022-06-30 | 87.00% 10-Q · filed 2022-07-27 | |||
| 2022-03-31 | 87.31% 10-Q · filed 2022-04-27 | |||
| 2021-12-31 | 84.70% 10-K · filed 2024-02-07 | |||
| 2021-09-30 | 84.06% 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | 83.92% 10-Q · filed 2021-07-28 | |||
| 2021-03-31 | 83.92% 10-Q · filed 2021-04-28 | |||
| 2020-12-31 | 77.30% 10-K · filed 2022-02-09 | |||
| 2020-09-30 | 77.09% 10-Q · filed 2020-10-28 | |||
| 2020-06-30 | 77.09% 10-Q · filed 2020-07-29 | |||
| 2020-03-31 | 76.92% 10-Q · filed 2020-04-30 | |||
| 2019-12-31 | 77.90% 10-K · filed 2021-02-17 | |||
| 2019-09-30 | 78.01% 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | 78.34% 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | 78.34% 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | 80.90% 10-K · filed 2020-02-26 | |||
| 2018-09-30 | 80.86% 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | 81.25% 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | 81.33% 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | 85.10% 10-K · filed 2019-03-13 | |||
| 2017-09-30 | 85.10% 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | 85.32% 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | 85.42% 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | 82.60% 10-K · filed 2018-03-07 | |||
| 2016-09-30 | 81.77% 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | 81.77% 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | 81.80% 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | 85.20% 10-K · filed 2016-03-08 | |||
| 2015-09-30 | 85.20% 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | 85.20% 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |